[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,80,108,133,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100626123","phase-1-topical-carboxytherapy-paste-following-microneedling-100626123",false,"NCT07431541","Topical Carboxytherapy Paste Following Microneedling","Effect of Topical Carboxytherapy Paste Following Microneedling","Inclusion Criteria:\n\n• English-speaking adults at least 18 years of age who elect to undergo microneedling for facial aging.\n\nExclusion Criteria:\n\n* Age under 18\n* Pregnant patients\n* Patients with other known medical conditions which affect facial cosmesis\n* Patients who have recently undergone surgery to the facial region or minimally invasive facial procedures within the past month",true,"ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Topical carboxytherapy refers to a gel paste that carries non-gaseous carbon dioxide (CO2). It is applied similarly to a face mask. Topical carboxytherapy has been shown to increase local blood flow and can help with wound healing. Few studies have researched how topical carboxytherapy can be used to aid skin rejuvenation in the field of facial plastic and reconstructive surgery. The goal of this study is to evaluate how topical carboxytherapy can improve skin healing after microneedling. Common temporary side effects of microneedling include redness and swelling, sometimes lasting up to a week post-procedure. If topical carboxytherapy reduces downtime related to side effects of microneedling, the investigators may offer this treatment to more microneedling patients in the future.",[28],"Skin",[30,31],"microneedling","carboxytherapy","NOT_YET_RECRUITING","2026-04-08",{"date":35,"type":36},"2026-04-14","ACTUAL",{"date":38,"type":21},"2026-07-01",{"date":40,"type":21},"2027-06-30",{"name":42,"class":43},"Vanderbilt University Medical Center","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100627891","examine-impact-of-topical-application-of-active-versus-placebo-on-the-skin-microbiome-in-sensitive-skin-100627891","NCT07454525","Examine Impact of Topical Application of Active Versus Placebo on the Skin Microbiome in Sensitive Skin.","SkinBiome","Inclusion Criteria:\n\n* Women aged 40-60 among all ethnicities and Fitzpatrick scale.\n* With self-assessed sensitive skin (SS10 \\> 13) and self-reported mild to moderate fine lines and wrinkles.\n* Must spend minimum 1 hour outside from 10am-4pm at least 5 times per week.\n* Residing within the same country on the mid to west coast (California, Nevada, Utah, Arizona, Colorado, New Mexico, Kansas, Oklahoma, Texas, Illinois, Kansas, Idaho, Nebraska, Montana).\n* Consider themselves to be in good health.\n* Willing to continue to use their current cosmetic products (foundation, blush, eyeshadow, sunscreen, etc.) and with the same routine\u002Ffrequency if they do not contain anti-aging ingredients.\n* Willing to refrain from using AHA, other peeling acids (PHA, BHA), prescription products such as retinoids or hydroquinone etc. during the study.\n* Willing to take skin swabs to support measures of the skin microbiome.\n* Must understand their role in the study, provide written informed consent, and fully participate over the 14-week period.\n* Willing to use the products provided within the study as instructed. Willing to change their current skincare routine and replace it with the given regimen for 14 weeks.\n* Willing to maintain diet and lifestyle (including physical exercise) during study period.\n\nExclusion Criteria:\n\n* Used any of the products to be tested in the claim study in the past 3 months. - Participation in a similar skin study within the past 30 days.\n* Have active skin disorders such as psoriasis, eczema, allergies, wounds, scars, or severe acne on their forehead.\n* Regular use of probiotic supplements\n* Consumption of fermented foods (including kefir, probiotic containing yoghurt, kombucha or other) for more than 5 times a week\n* Are orally or topically using or have used in the past 6 months: antibiotics, NSAIDS, antihistamines, immuno-suppressants, corticosteroids, prescription products such as retinoids, hydroquinone, or strong AHA treatments.\n* Have started hormonal treatment (e.g., contraceptives, fertility treatments, or HRT for menopause) within the past 3 months or in case they are on a treatment for more than 3 months they are unwilling to maintain a stable regimen for the duration of the study.\n* Pregnant or breastfeeding.\n* Any history of significant disease or medical condition to alter skin appearances such as type 2 diabetes, cancer, renal disorders or hepatic dysfunction.\n* Individuals who have had medical procedures in their face such as laser resurfacing (or any type of laser treatment ex. photo depilation), plastic surgery (including Botox) within the last 12 months or history of UV radiation (tanning and facial lamps) within the last 3 months.\n* Active Vitiligo or any other chronic skin conditions.\n* Individuals with any history that, in the investigator's opinion, indicates potential harm to the subject or could jeopardize the validity of the study.\n* History of poor cooperation, non-compliance, unreliability, or unwillingness to follow the research protocol and timeline.","FEMALE","40 Years","60 Years",{"count":55,"type":21},45,[57],"NA","The purpose of this study is to build insights to understand how the placebo and active impacts the skin microbiome in women with high skin sensitivity (SS10 \\> 13) and sun exposure. Microbiome samples will be taken at baseline after 2 weeks of using the placebo (base without active) as a run-in period followed by the usage of placebo for an additional 4 weeks. The participants will then start the usage of active formula for an additional 8 weeks with microbiome samples collected at the 10-week and 14-week. This will allow us to observe how the microbiome changes over time after the product usage of both placebo and active formulations relative to the pre-regimen condition. In addition, headshot photos will be taken using the Haut AI application at each time point concurrent to the microbiome sample collection to examine changes in skin appearances after the regimen.",[28,60,61,62],"Skin Microbiome","Skin Microbiota","Skin Ageing",[64,28,65,66,67,68,69],"Microbiome","Skin ageing","Fine lines","Face Skin","Sun exposure","Skin appearance","2026-03-04",{"date":72,"type":36},"2026-03-06",{"date":74,"type":21},"2026-02",{"date":76,"type":21},"2026-06",{"name":78,"class":79},"AB Biotics, SA","INDUSTRY",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100385974","phase-2-trial-of-ixazomib-for-kaposi-sarcoma-100385974","NCT04305691","Trial of Ixazomib for Kaposi Sarcoma","A Phase 2 Trial of Ixazomib for Kaposi Sarcoma","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document\n* Participants must have histologically or cytologically confirmed cutaneous Kaposi sarcoma. Participants must have measurable disease with a minimum of five bi-dimensionally measurable KS cutaneous marker lesions. If fewer than five bi-dimensionally measurable marker lesions are available, the total surface area of the marker lesion(s) must be \\>= 700 mm\\^2\n* Participants must have documentation of HIV status. If HIV negative, documentation of a negative HIV rapid test within 21 days before enrollment. If HIV positive, documentation of HIV-1 infection by means of any one of the following:\n\n  * Documentation of HIV diagnosis in the medical record by a licensed health care provider\n  * Documentation of receipt of antiretroviral therapy (ART) (at least two different medications that do not constitute a prescription for pre exposure prophylaxis \\[PrEP\\]) by a licensed health care provider. Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name\n  * HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating \\> 1000 RNA copies\u002FmL\n  * Any licensed HIV screening antibody and\u002For HIV antibody\u002Fantigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or Multispot HIV-1\u002FHIV-2 Rapid Test or HIV Antibody HIV-1\u002FHIV-2 Differentiation Assay\n\n    * Note: The term \"licensed\" refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally (e.g., United States \\[U.S.\\] Food and Drug Administration \\[FDA\\]). WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an extracellular interactome assay (E\u002FCIA )that is based on a different antigen preparation and\u002For different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (Karnofsky \\>= 50%)\n* Life expectancy of greater than 3 months\n* Absolute neutrophil count: \\>= 1,000\u002Fmm\\^3 (within 21 days before enrollment)\n* Hemoglobin: \\> 8 g\u002FdL (within 21 days before enrollment)\n* Platelets: \\>= 75,000\u002Fmm\\^3 (within 21 days before enrollment). Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days before study enrollment\n* Total bilirubin =\\\u003C 1.5 x the upper limit of the normal range (ULN) (within 21 days before enrollment)\n\n  * If the elevated bilirubin is felt to be secondary to indinavir or atazanavir therapy, then subjects will be allowed on protocol without any limit on the total bilirubin if the direct bilirubin is normal\n* Creatinine:\n\n  * Serum creatinine levels within normal institutional limits; or, creatinine clearance \\>= 30 mL\u002Fmin (as calculated per the Cockcroft-Gault Equation (within 21 days before enrollment)\n* Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification within 6 months before study enrollment. To be eligible for this trial, participants must be class 2B or better within 6 months before enrollment\n* Ixazomib can cause fetal harm. For this reason and because proteasome inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control and another method such as hormone contraception simultaneously; abstinence) before study entry, the duration of study participation, and 90 days after completion of ixazomib administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception or abstain from heterosexual contact before the study, for the duration of study participation, and for 90 days after completion of ixazomib administration\n* If HIV positive, participants must have been on antiretroviral therapy (ART) with optimum anti-viral response for at least 12 weeks. Three-drug ART regimens which include a protease inhibitor or a nucleoside reverse transcriptase inhibitor are acceptable, as is the recently FDA-approved injectable ART regimen, cabotegravir with rilpivirine. Additional appropriate regimens in management of HIV as specified in https:\u002F\u002Fclinicalinfo.hiv.gov\u002F are acceptable as long as they do not include moderate or strong CYP3A4 inducers. Changes of antiretroviral therapy within the prior 12 weeks for toxicity\u002Fconvenience reasons are allowed (as long as participants are on a stable regimen for 4 weeks per Section 3.1.11). However, if changes in anti-HIV therapy are due to inadequate HIV control and occurred within the 3 months prior to protocol consent, the patient is not eligible until 12 weeks after optimal control is reached.\n* If HIV positive, must have been on a STABLE anti-retroviral therapy for at least 4 weeks. The non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and etravirine are moderate CYP3A4 inducers which will reduce ixazomib exposure and are therefore prohibited. Potential participants requiring change of antiretroviral therapy to avoid moderate to strong CYP3A4 inducers or to pursue better HIV management with an alternate antiretroviral regimen should defer enrollment until completing 4 weeks of the new ART regimen. There should be no intention to change the regimen for the duration of the study.\n* HIV positive participants must not show recent improvement in KS on ART alone that may confound response evaluation, within the following parameters:\n\n  * If on ART 12 to 24 weeks, participants must show a burden of disease requiring further systemic KS-directed treatment (i.e. advanced cutaneous disease, presence of lymphedema or asymptomatic visceral disease, painful lesions) or evidence of KS progression:\n  * i.e. any new lesion(s);\n  * spreading of lesions by any measurable degree;\n  * development of ulceration;\n  * worsening edema documented by circumferential measure of limb or body;\n  * increase in symptoms such as pain, including negative psychological impact;\n  * any degree of disease worsening by imaging that would prompt expert assessment to recommend further systemic treatment with delay\n  * If on ART for \\>24 weeks, must show no evidence of regression in last 8 weeks\n* Patients who have residual active KS lesions (not merely tattoo effect) after receipt of recent KS-directed therapy are eligible to participate even if there was no interval progression since completion of therapy as long as: (1) the degree of residual disease merits systemic therapy (i.e. advanced cutaneous disease, presence of lymphedema or asymptomatic visceral disease, painful lesions)); and (2) at least 4 weeks have passed since receipt of the most recent KS-directed therapy.\n\nExclusion Criteria:\n\n* Participants who are receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ixazomib or other agents used in study\n* Chronic systemic treatment using strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort is not allowed. Patients who are on chronic use of strong CYP3A inducers must come off 14 days before receiving ixazomib treatment. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment\u002Finformed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months; or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements. This includes infections requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment but excludes ongoing antibiotic therapy for opportunistic infection (OI) prophylaxis\n* Participants with a second prior or concurrent malignancy that has a natural history or treatment regimen that has the potential to interfere with the safety or efficacy assessment of the investigational regimen\n* Pregnant women are excluded from this study because ixazomib is expected to cause fetal harm if used during pregnancy. It is not known if ixazomib is excreted into breast milk, but due to the potential for serious adverse events in a nursing infant, breastfeeding must be discontinued during therapy and for 90 days after the last ixazomib dose\n* Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) before entering the study\n* Participants who have not recovered from other adverse events due to prior anti-cancer therapy (i.e., have residual toxicity \\> grade 1), excluding alopecia\n* Participants who are seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen \\[HBsAg\\]). All participants will be required to be screened for hepatitis B. Participants with resolved infection (i.e. participants who are HBsAg negative but positive for antibodies to hepatitis B core antigen (anti-HBc) and\u002For antibodies to hepatitis B surface antigen (anti-HBs) must be screened using real-time polymerase chain reaction (PCR) measurement of HBV deoxyribonucleic acid (DNA) levels. Participants who are PCR positive will be excluded. EXCEPTION: Participants with serologic findings suggestive of hepatitis B virus (HBV) vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR\n* Participants diagnosed with hepatitis C who are hepatitis C antibody positive, whether hepatitis C RNA level is measurable or not, must have no evidence of cirrhosis and have liver function tests that conform to the protocol inclusion criteria\n* Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing\n* Participants with grade 2 or higher peripheral neuropathy (i.e., painful neuropathy) on clinical examination during the screening period\n* Major surgery within 14 days before enrollment\n* Participants with symptomatic visceral Kaposi sarcoma\n* Participants who have had prior treatment of Kaposi sarcoma with a proteasome inhibitor within the last 2 years or with ixazomib at any time.",{"count":88,"type":21},41,[25],"This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.",[92,28],"Kaposi Sarcoma",[92,94,28,95],"HIV","ixazomib","RECRUITING","2026-02-25",{"date":99,"type":36},"2026-02-27",{"date":101,"type":36},"2023-11-07",{"date":103,"type":21},"2029-03-15",{"name":105,"class":106},"AIDS Malignancy Consortium","NETWORK",11,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":16,"sex":51,"minAge":116,"maxAge":53,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100619355","clinical-trial-to-assess-the-efficacy-and-safety-of-a-cosmetic-product-in-individuals-showing-signs-of-cutaneous-aging-100619355","NCT07343544","Clinical Trial to Assess the Efficacy and Safety of a Cosmetic Product in Individuals Showing Signs of Cutaneous Aging.","Estudio clínico Para Evaluar Los Efectos y la Seguridad de un Producto cosmético en Sujetos Con Signos de Envejecimiento cutáneo.","SkinMeter","Inclusion Criteria:\n\n* Female participants.\n* Age between 35 and 60 years.\n* All skin types (combination, oily, dry, and\u002For normal).\n* Skin condition: 50% sensitive skin and 50% normal skin.\n* Visible signs of facial skin aging (mild\u002Fmoderate wrinkles and\u002For pigmentation spots).\n* Willingness to participate voluntarily and provide written informed consent.\n* Ability to understand the study objectives and procedures.\n* Good general health (physical and mental).\n* Availability to attend all scheduled visits at the research center.\n* Discontinuation of anti-aging products on the experimental area (face) at least 7 days prior to study start.\n* Commitment not to change facial hygiene routines during the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* History of allergy to cosmetic products and\u002For dietary supplements.\n* Known allergy or hypersensitivity to any component of the product.\n* History or current diagnosis of cancer.\n* Active skin diseases or infections in the experimental area.\n* Recent or planned surgical or aesthetic interventions in the experimental area Medical-aesthetic treatments on the face within the last 6 months (e.g., botulinum toxin, hyaluronic acid, laser, radiofrequency, HIFU, deep chemical peels, microneedling with actives).\n* Relevant dermatological conditions in the experimental area (eczema, psoriasis, allergic\u002Fcontact dermatitis, etc.).\n* Use of topical or systemic medications affecting the skin (retinoids, antibiotics, corticosteroids) within the last 3 months.\n* Current or planned use of supplements that may affect skin health (collagen, antioxidant vitamins A\u002FC\u002FE, zinc, omega-3, oral probiotics\u002Fprebiotics).\n* Systemic diseases such as autoimmune disorders (rheumatoid arthritis, lupus, multiple sclerosis), chronic viral infections (HIV, hepatitis B\u002FC), or severe metabolic diseases.\n* Use of any product other than the study product on the experimental area during the study.\n* Planned significant changes in health habits during the study (diet, physical activity, structured exercise programs).\n* Recent or planned changes in hormonal contraceptives.\n* Sun or UVA exposure during the study.\n* Participation in another clinical study involving the same experimental area\n* Application of any product on the experimental area on the day of study initiation.\n* Any medical condition, at the investigator's discretion, that may interfere with protocol adherence or participant safety.","35 Years",{"count":55,"type":21},[57],"This clinical study investigates the effects and safety of a topical cosmetic product containing postbiotics (Bifida ferment extract and Pediococcus ferment extract) in women aged 35-60 with visible signs of skin aging.\n\nThe study is a 3-month, single-center, intra-subject controlled trial involving 45 Caucasian women with sensitive or normal skin. Participants will apply 1 ml of the product twice daily. Clinical evaluations will be conducted at baseline and at 1 month, 2 months, and 3 months, using validated dermatological scales and non-invasive instruments (AEVA3D, Mexameter®, MoistureMap®, Cutometer®, Tewameter®, Clarius®, Glossymeter®).\n\nSafety will be assessed through systematic monitoring of adverse events, with serious adverse events expected to remain below 1%. Subjective perception will be evaluated via structured questionnaires.",[28,62,121,122,123],"Fine Lines","Face Aging\u002FPhoto Aging of Moderate Grade","Face Skin Photoaging",[67,125,28,65],"Postbiotics","2026-01-08",{"date":128,"type":36},"2026-01-15",{"date":74,"type":21},{"date":131,"type":21},"2026-05",{"name":78,"class":79},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100615882","see-the-impact-beems-blue-light-therapy-has-on-your-skin-health-100615882","NCT07298382","See the Impact Beem's Blue Light Therapy Has on Your Skin Health!","Inclusion Criteria:\n\n* Can read and understand English.\n* US resident.\n* Willing and able to follow the requirements of the protocol.\n\nExclusion Criteria:\n\n* Individuals with Epilepsy\n* Individuals with Photosensitivity\n* Individuals with eye conditions\n* Pregnant individuals\n* Individuals with skin sensitivity\n* Individuals taking certain light-sensitive medications",{"count":140,"type":21},100,[57],"Participants will experience a rejuvenating twice-weekly light therapy journey that blends the power of blue, red, and infrared light. Each 20-minute session flows through three phases: starting with refreshing blue light to awaken and energize, then moving into soothing red light, and finishing with deeply nourishing infrared light. This unique protocol is designed to help unlock healthier-looking skin and boost your natural glow.",[28],"2025-12-19",{"date":146,"type":36},"2025-12-23",{"date":148,"type":36},"2025-10-06",{"date":150,"type":21},"2026-10-06",{"name":152,"class":79},"Efforia, Inc",1,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":16,"sex":17,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":153},"100607468","in-vivo-cross-modal-imaging-of-skin-100607468","NCT07188948","In Vivo Cross-Modal Imaging of Skin","In Vivo Cross-Modal Imaging of Skin - VISION2","VISION2","Inclusion Criteria:\n\nParticipants, ages 2 - 90 years old\n\nParticipant, or guardian, if applicable, must be willing to provide written informed consent prior to enrollment and agree to comply with protocol requirements. If applicable, child must be willing to provide written assent prior to enrollment and agree to comply with protocol requirements.\n\nParticipant or guardian, if applicable, must have sufficient mental capacity to understand the Informed Consent and provide clinically relevant and reliable feedback regarding their experience with the device.\n\nParticipant and guardian, if applicable, must comply with the protocol requirements.\n\nParticipant or guardian, if applicable, must agree that anonymized personal data will be made available to Study Sponsor and requisite regional and international regulatory bodies\n\nExclusion Criteria:\n\nAny general health condition or systemic disease that may represent, in the opinion of the Principal Investigator, a potential increased risk associated with device use\n\nCurrently infected with a communicable skin infection (e.g., shingles or methicillin-resistant S. aureus), which does not include local and minimally pathogenic or non-pathogenic infections distant from the imaging location(s) (e.g., warts, acne)\n\nAny known allergies to any materials used in the preparation of skin and\u002For device use\n\nHas a temporary or permanent electrical implanted medical device\n\n\\-","2 Years","90 Years",{"count":165,"type":21},15,"OBSERVATIONAL","The overall objective of this study is to use VIO\u002FFG-30350 (\"VIO\") to observe microscopic skin structure in people of different skin health at different anatomic locations and correlate microscopic features with macroscopic features.",[28],"2025-09-16",{"date":171,"type":36},"2025-09-23",{"date":173,"type":36},"2025-09-02",{"date":175,"type":21},"2025-09-30",{"name":177,"class":79},"Gabriel Sanchez"]